Market Newsdesk

THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.

The feedback was provided in response to a request made by Lexicon following the completion of the SOLOIST and SCORED studies relating to the potential submission of an NDA based on the results of such studies, taking into account their early close-out and other considerations. This regulatory feedback clears a key hurdle for partnership discussions around sotagliflozin in heart failure and enables a potential NDA filing in 2021.

Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 39^th Annual J.P. Morgan Healthcare Conference today at 2:50 p.m. ET. A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com.

About the SOLOIST and SCORED Studies

SOLOIST was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 1,222 patients with type 2 diabetes who had recently been hospitalized for worsening heart failure. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.

SCORED was a multi-center, randomized, double-blinded, placebo-controlled Phase 3 study evaluating the cardiovascular efficacy of sotagliflozin versus placebo when added to standard of care in 10,584 patients with type 2 diabetes, chronic kidney disease with eGFR of 25 to 60 ml per minute per 1.73 m² of body-surface area, and risks for cardiovascular disease. The primary endpoint was the total number of events comprised of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure in patients treated with sotagliflozin compared with placebo.

Both SOLOIST and SCORED achieved their respective primary endpoints. Results from both studies were presented at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.”

About Sotagliflozin

Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m², who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s clinical development of and regulatory filings for sotagliflozin, partnership discussions relating to sotagliflozin and the potential therapeutic and commercial potential of sotagliflozin, as well as Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Inquiries:

Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
[email protected]

New York, Jan. 14, 2021 (GLOBE NEWSWIRE) — The Blinc Group, Inc., the regulatory-focused designer and provider of premium, customized and bespoke vaporizer technologies, has successfully raised a pre-Series A bridge financing of $1.5 million led by Equitas Partners Fund, WGD Capital, LP, and 7thirty Capital.

“The Blinc Group puts quality and safety at the forefront of its vape technology and since day one, that dedication to the highest standards has brought us the endorsement of institutional investors focused on the cannabis industry. Our team navigated 2019’s vape crisis helping set standards and advise regulators on testing and compliance, and last year the company saw our best quarter yet amid the COVID-19 pandemic as the industry learned the benefits of safety and traceability. We have shown that we are a resilient company that puts consumers first, which has made all the difference,” said Arnaud Dumas de Rauly, CEO and co-founder of the Blinc Group.

In 2020, Blinc Group more than tripled its orders with over 330% YOY growth, showcasing the technology company’s ability to scale and flourish in a difficult regulatory landscape. They attribute much of their success to the emphasis the company placed on safety, compliance and maintained throughout the vape crisis of 2019 and the Coronavirus pandemic. The company has won clients from around the globe including Canadian heavyweights because of its unique ability to meet Health Canada’s rigorous standards, a success unmatched by most other vape companies.

“We began underwriting our initial investment in Blinc near the onset of the so-called vape crisis in 2019 and it became quickly apparent that the team’s experience within the vape technology space and its focus on quality, traceability and customer service would see them through and enable them to emerge as a market leader. While others turned more attention towards safer vaping products after the crisis, safety had always been a major pillar of Blinc’s products and part of its DNA, which attracted us as investors and gave us confidence that they would be able to substantially expand their business into Canada and elsewhere,” said Andi Goldman, Managing Member and co-founder of the Equitas Partners Fund.

The Blinc Group has also stayed ahead of the industry in part due to its strong ties in Shenzhen, China, and employing a manufacturing line dedicated to their products, which helped eliminate hiccups in the supply chain. The Company’s China-based team is the backbone of Blinc’s “Powered By Blinc” offering, a certified product manufactured to the highest international standards of safety and compliance with complete quality control and full traceability of the product, process, and each sub-component across the entire supply chain.

“We have watched the Blinc team over the past few years as they have grown their business and dedicated their focus to safety and traceablity within the vape hardware sector.  Blinc’s reputation for putting these important factors first has secured customer wins with some of the leading cannabis operators in North America”, said Michael Mitgang, Managing Director and Co- Founder of the WGD Opportunity Fund.

Proceeds from this financing will go towards expanding Blinc’s sales team, opening an office in Toronto, as well as expanding the team in Shenzhen, and the research and development of new innovative materials and vape technologies.

“The vape category is one of the primary revenue drivers in every market and satisfies the demands of some of the most committed cannabis consumers. Providing high-quality products is a must for any brand looking to win and retain loyal shoppers,” said 7thirty’s Director of Research, Ben Richardson “The Blinc Group’s focus on vape safety and compliance, in addition to CEO Arnaud Dumas de Rauly’s leadership roles with International and European committees on vaping products, position the Company as a leading voice in this fast-growing category.”

In 2020, The Blinc Group worked closely with Colorado’s Science & Policy Committee on the adoption of new testing standards for the emissions from vape devices. This kind of work is just one example of the dedication that the Blinc Group team puts on aligning the cannabis industry with best practices for the safest products possible.

The Blinc Group also received additional funding from the Arcview Collective Fund and the Panther Opportunity Fund.

###

About the Blinc Group


Headquartered in New York City, the Blinc Group designs, develops, supplies, and supports premium cannabis vaping hardware. The company offers a curated collection of proven cartridges, batteries, ready to use vaporizers and complete bespoke device development to multi-state operators, licensed producers, and brands. Blinc completes the value chain by providing its clients access to a suite of support services ranging from research and development, production, testing, standard operating procedures, training and all the way to go-to-market strategy and brand communications consulting. With full control of the supply chain, the company’s unique “Powered by Blinc” process enables clients to provide innovative, safe, and quality-controlled products to cannabis consumers worldwide.

About Lead Investors


Equitas Partners Fund LLC
Founded in 2018, Equitas Partners Fund is a U.S. based investment fund focused on early-stage investments in the legal cannabis industry, primarily in the US and Canada, in both plant-touching and ancillary companies. The Equitas team brings decades of institutional investing and corporate operating experience (in both cannabis and other industries) to the developing and fast-growing legal cannabis industry. Equitas places a strong emphasis on company management, investment valuation, and extensive due diligence to build a well-diversified portfolio of legal cannabis investments. 

WGD Capital, LP

WGD Capital, with offices in the San Francisco Bay Area, Vancouver, Canada and Tel Aviv, Israel, is focused on investing in and managing a portfolio of innovated market-leading businesses along the cannabis industry value chain. The goal of the WGD Opportunity Fund is to generate attractive returns while mitigating risk through professional management, diversification, structured investments, and corporate governance. 

7thirty Capital

7thirty Capital provides a full range of capital services to investors and companies in the frontier cannabis markets. The 7thirty team includes investment veterans with over 25 years of Wall Street experience in commodities, agriculture, consumer goods and technology. 7thirty is headquartered in Boulder, Colorado with offices in New York City.

Gretchen Gailey
The Blinc Group
2024893821
[email protected]

AUSTIN, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. (“SCV”) today announced the availability of a new interview with the leadership of Marijuana Company of America Inc. (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp corporation. The interview focusses on the recent shareholder update and 2021 guidance issued by the Company on January 12^th, 2021, the 2020 highlights for the Company, along with with management’s commentary on the state of cannabis in America today and more.

In the interview, Quintero outlined several key achievements produced by Company, all while enduring the difficult business climate brought on by the global pandemic. MCOA management was able to restructure the Company making it far more cost-effective operation through reducing operating expenses, liabilities and leveraging unique collaborations with other cannabis and hemp technological innovators like Cannabis Global Inc. (OTC: CBGL).

While discussing the goals for the Company in 2021, Quintero tells Smith. “Currently we are in the process of deploying our new eCommerce platform which we believe will have a big impact on our retail sales. We are rebranding our products and promoting them via a robust awareness campaign. In addition, MCOA will continue to expand our reach and teams globally in South America and Europe, we will take full advantage in the favorable political environment for CBD and hemp in the United States, and we seek out new opportunities here in the U.S. and abroad.” Mr. Quintero added, “We believe are clearly focused on the right path. We are a lean and mean operation building product awareness for CBD and all of our products on a large scale.”

The full interview can be heard at: https://www.smallcapvoice.com/january-interview-marijuana-company-of-america-mcoa/.

About Marijuana Company of America, Inc.

MCOA is an emerging industry leader with focus in product development and sales & marketing with its proprietary botanical ingredients legal hemp-based cannabidiol (“CBD”) quality products under the brand name “hempSMART™”. The Company’s premium quality products are double lab tested for purity and potency and sold to wholesalers, distributors, via online e commerce consumer platform, and a proven network affiliate marketing program. The Company recently announced plans for international sales, production, and marketing expansion.

For more information, please visit: https://www.marijuanacompanyofamerica.com/

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at

Facebook: https://www.facebook.com/SmallCapVoice/
Twitter: https://twitter.com/smallcapvoice
Instagram: https://www.instagram.com/smallcapvoice/

Forward-Looking Information

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

MCOA Contact:

Tel: 888-777-4362
Email: [email protected]

SmallCapVoice.com Contact:

Stuart T. Smith
512-267-2430
[email protected]

Source: SmallCapVoice.com

Investors with losses of over $250,000 are encouraged to contact the firm before  January 19, 2021; click here to submit trade information

LOS ANGELES, Jan. 14, 2021 (GLOBE NEWSWIRE) — ​The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of K12, Inc. (NASDAQ:LRN) investors that acquired shares between April 27, 2020 and September 18, 2020. Investors have until January 19, 2021 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in the complaint that throughout the Class Period, Defendants made misleading and/or false  statements and/or failed to disclose that: (1) K12 lacked the expertise, infrastructure, and  technological capabilities, to support the increased demand for blended and virtual education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protections and protocols to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of training and administrative support to students, teachers, and parents; (4) and K12’s officers lacked a reasonable basis for their positive statements about their prospects, operations, and business.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 19, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

NAPLES, Fla., Jan. 14, 2021 (GLOBE NEWSWIRE) — Beasley Broadcast Group, Inc. (Nasdaq: BBGI) (“Beasley” or the “Company”), a multi-platform media company, today announced preliminary unaudited financial results for the three months ended December 31, 2020.

• Beasley generated net revenue of approximately $67.4 million to $67.9 million for the three months ended December 31, 2020, compared to reported net revenue of $72.1 million for the three months ended December 31, 2019, representing a year-over-year decrease of between 5.8% and 6.5%. Beasley’s estimated fourth quarter 2020 net revenue reflects a year-over-year decrease in commercial advertising revenue due to the ongoing impact of the COVID-19 pandemic, partially offset by growth in digital, esports and political revenue.
• Fourth quarter 2020 Station Operating Income (SOI, a non-GAAP financial measure) increased by approximately 23.1% to 28.8% year-over-year to approximately $19.2 million to $20.1 million, compared to reported fourth quarter 2019 SOI of $15.6 million. Fourth quarter 2020 SOI less corporate expenses increased by approximately 47.9% to 58.8% year-over-year to approximately $15.0 million to $16.1 million, compared to fourth quarter 2019 SOI less corporate expenses of $10.1 million.
• Fourth quarter 2020 EBITDA increased by approximately 25.0% to 33.8% year-over-year to approximately $17.0 million to $18.2 million, compared to reported fourth quarter 2019 EBITDA of $13.6 million.
• The year-over-year increases in SOI, SOI less corporate expenses and EBITDA are primarily attributable to Beasley’s initiatives to address the COVID-19 pandemic, including reducing operating expenses and corporate overhead and realigning our company-wide cost structure, the benefit of political advertising, as well as an expected gain on a land sale that occurred during the fourth quarter of 2020.

Commenting on the preliminary financial results, Caroline Beasley, Chief Executive Officer, said, “We expect to report top-line revenue improvement in the second half of the year, with sequential quarter-over-quarter growth in both the third and fourth quarters of 2020. Our preliminary fourth quarter performance also demonstrates the significant operating benefits from the actions we took earlier this year to address the pandemic, including reducing station operating expenses and negotiating discounts with landlords, service providers and partners. Although it is difficult to predict what the impact of COVID-19 will be in the coming months, we remain optimistic that the commercial advertising market will return to more normalized revenue levels as we move further into the year, following broad vaccine distribution.”

The Company’s financial results for the three months ended December 31, 2020 are not yet complete. Accordingly, the preliminary, unaudited results below are forward-looking statements based solely on information available to the Company as of the date of this release, and the Company undertakes no obligation to update this information, except as may be required by law. These preliminary, unaudited results are based on the most current information available to management following its initial review of operations for the quarter ended December 31, 2020 and remain subject to completion of Beasley’s customary financial closing procedures, including external independent auditor review. In light of the foregoing, you are cautioned not to place undue reliance on these preliminary, unaudited results. Beasley expects to announce full fourth quarter and year end results and host a webcast conference call in February 2021.

Beasley Media Group Preliminary Summary Financial Results
(in millions)	Estimated 4Q20 Range	Reported 4Q19		% Change
Net Revenue	$67.4 – $67.9	$72.1		(5.8)% – (6.5)%
SOI	$19.2 – $20.1	$15.6		23.1% – 28.8%
SOI Less Corporate Expenses	$15.0 – $16.1	$10.1		47.9% – 58.8%
EBITDA	$17.0 – $18.2	$13.6		25.0% – 33.8%

About Beasley Broadcast Group

Celebrating its 60th anniversary this year, Beasley Broadcast Group, Inc., (www.bbgi.com) was founded in 1961 by George G. Beasley who remains the Company’s Chairman of the Board. Beasley Broadcast Group owns and operates 63 stations (47 FM and 16 AM) in 15 large- and mid-size markets in the United States. Approximately 20 million consumers listen to Beasley radio stations weekly over-the-air, online and on smartphones and tablets, and millions regularly engage with the Company’s brands and personalities through digital platforms such as Facebook, Twitter, text, apps and email. Beasley recently acquired a majority interest in the Overwatch League’s Houston Outlaws esports team and owns BeasleyXP, a national esports content hub. For more information, please visit www.bbgi.com.

Non-GAAP Financial Measures
Station Operating Income (SOI) consists of net revenue less station operating expenses. We define station operating expenses as cost of services and selling, general and administrative expenses. SOI Less Corporate Expenses consists of SOI minus corporate expenses.

EBITDA consists of net income attributable to BBGI stockholders before interest expense, income tax expense and depreciation and amortization.

SOI, SOI Less Corporate Expenses and EBITDA are measures widely used in the radio broadcast industry. The Company recognizes that because SOI, SOI Less Corporate Expenses and EBITDA are not calculated in accordance with GAAP, they are not necessarily comparable to similarly titled measures employed by other companies. However, management believes that SOI, SOI Less Corporate Expenses and EBITDA provide meaningful information to investors because they are important measures of how effectively we operate our business (i.e., operate radio stations) and assist investors in comparing our operating performance with that of other radio companies.

The Company is unable to present a quantitative reconciliation of preliminary SOI, SOI Less Corporate Expenses and EBITDA for the three months ended December 31, 2020 to the most directly comparable GAAP financial measure, net income, because management cannot reliably predict all of the necessary components of the GAAP financial measure without unreasonable efforts. Net income includes several significant items, such as impairment losses, income taxes and earnings of unconsolidated affiliates. The decisions and events that typically lead to the recognition of these and other similar items are complex and inherently unpredictable, and the amount recognized for each item can vary significantly. Accordingly, the Company is unable to provide a reconciliation of preliminary SOI, SOI Less Corporate Expenses and EBITDA to net income or address the probable significance of the unavailable information, which could be material to the Company’s future financial results. Reconciliations to the most directly comparable GAAP measure for the three months ended December 31, 2019 are included in the tables that follow.

Note Regarding Forward-Looking Statements

Statements in this release that are “forward-looking statements” are based upon current expectations and assumptions, and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Words or expressions such as “looking ahead,” “look forward,” “intends,” “believe,” “hope,” “plan,” “expects,” “expected,” “anticipates” or variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about expected income; shareholder value; revenues; and growth. Key risks are described in our reports filed with the SEC including in our annual report on Form 10-K and quarterly reports on Form 10-Q. Readers should note that forward-looking statements are subject to change and to inherent risks and uncertainties and may be impacted by several factors, including:

• the effects of the COVID-19 pandemic, including its potential effects on the economic environment and our results of operations, liquidity and financial condition, and the increased risk of impairments of our Federal Communications Commission (“FCC”) licenses and/or goodwill, as well as any changes to federal, state or local government laws, regulations or orders in connection with the pandemic;
• external economic forces that could have a material adverse impact on our advertising revenues and results of operations;
• the ability of our radio stations to compete effectively in their respective markets for advertising revenues;
• our ability to develop compelling and differentiated digital content, products and services;
• audience acceptance of our content, particularly our radio programs;
• our ability to respond to changes in technology, standards and services that affect the radio industry;
• our dependence on federally issued licenses subject to extensive federal regulation;
• actions by the FCC or new legislation affecting the radio industry;
• our dependence on selected market clusters of radio stations for a material portion of our net revenue;
• credit risk on our accounts receivable;
• the risk that our FCC licenses and/or goodwill could become impaired;
• our substantial debt levels and the potential effect of restrictive debt covenants on our operational flexibility and ability to pay dividends, including restrictions on the ability to pay dividends in the near term as a result of the amendment to the our credit agreement;
• the potential effects of hurricanes on our corporate offices and radio stations;
• the failure or destruction of the internet, satellite systems and transmitter facilities that we depend upon to distribute our programming;
• disruptions or security breaches of our information technology infrastructure;
• the loss of key personnel;
• our ability to integrate acquired businesses and achieve fully the strategic and financial objectives related thereto and their impact on our financial condition and results of operations;
• the fact that we are controlled by the Beasley family, which creates difficulties for any attempt to gain control of the Company; and
• other economic, business, competitive, and regulatory factors affecting our business, including those set forth in our filings with the SEC.

Our actual performance and results could differ materially because of these factors and other factors discussed in our SEC filings, including but not limited to our annual reports on Form 10-K or quarterly reports on Form 10-Q, copies of which can be obtained from the SEC, www.sec.gov, or our website, www.bbgi.com. All information in this release is as of January 14, 2021, and we undertake no obligation to update the information contained herein to actual results or changes to our expectations.

-tables follow-

Reconciliation of Net Income to SOI and SOI Less Corporate Expenses – Unaudited
		Three Months Ended December 31, 2019
Net income		$	4,717,479
Corporate expenses			5,496,797
Transaction expenses			407,011
Depreciation and amortization			1,970,974
Change in fair value of contingent consideration			—
Gain on dispositions			(17,111,605	)
Impairment losses			13,657,941
Interest expense			4,488,586
Loss on modification of long-term debt			—
Other income (expense), net			(34,568	)
Income tax expense			2,331,124
Equity in earnings of unconsolidated affiliates			(283,205	)
SOI		$	15,640,534
Less: Corporate Expenses			5,496,797
SOI Less Corporate Expenses		$	10,143,737

Reconciliation of Net Income Attributable to BBGI Stockholders to EBITDA
		Three Months Ended December 31, 2019
Net income Attributable to BBGI Stockholders		$	4,784,061
Interest Expense			4,488,586
Income Tax Expense			2,331,124
Depreciation and amortization			1,970,974
EBITDA		$	13,574,745

CONTACT:
B. Caroline Beasley	Joseph Jaffoni, Jennifer Neuman
Chief Executive Officer	JCIR
Beasley Broadcast Group, Inc.	212/835-8500 or [email protected]
239/263-5000 or [email protected]

BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) —


Cocrystal Pharma, Inc.

(Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that its President Sam Lee, Ph.D. will be making a presentation at the virtual 3^rd Annual reimagine Health Research Symposium, University of Arizona College of Medicine, being held January 21, 2021.

During a presentation titled “Application of structure-based drug design platform technology for developing broad spectrum COVID-19, influenza, and HCV antivirals,” Dr. Lee will discuss the use of the Company’s platform technology to develop broad-spectrum antiviral inhibitors.

“We are delighted to have the opportunity to present Cocrystal’s enabling technology as used for HCV, influenza and COVID-19 drug discovery,” said Dr. Lee. “Last month we announced the selection of a lead compound for further development against coronaviruses, including SARS-CoV-2, as we advance our COVID-19 program.”

About the reimagine Health Research Symposium

The 3^rd Annual reimagine Health Research Symposium will focus on current topics in the areas of intervention and prevention of important diseases that are impacting humankind. It will emphasize approaches for a variety of diseases and crises—including COVID-19, cardiovascular disease, cancer, opioid addiction and the need to develop novel antibiotics. Attendees will learn from and engage with leading experts who will present and discuss contemporary treatment and prevention strategies in the areas of drug discovery, vaccine development, addiction management and the use of artificial intelligence, as well as the ethical and social factors contributing to these approaches. The reimagine Health Research Symposium is co-sponsored and planned by the Arizona Biomedical Research Centre, the University of Arizona College of Medicine – Phoenix Research Office and the Flinn Foundation. More information about the symposium is available here.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:

LHA Investor Relations
Jody Cain
310-691-7100
[email protected]

# # #

NEW YORK, Jan. 14, 2021 (GLOBE NEWSWIRE) — Venture For ClimateTech has begun accepting applications for its first cohort. Venture for ClimateTech is a new global non-profit venture studio + accelerator providing innovators with the non-dilutive funding they need to de-risk their opportunity, as well as the tools, training, and talent to begin building and launching a company around their impactful climate tech solution. Participation in the free six-month program—which will be held virtually—entails a competitive selection process.

Innovators and founders who have an idea or technology that has the potential to substantially reduce greenhouse gases are encouraged to apply. Applicants can be located anywhere in the world and should be interested in benefiting the climate tech ecosystem, including in New York State. Particular segments of interest include hardware, software, or business model solutions for buildings, transportation, energy storage, grid, fintech, food and agtech. Solutions that reach, are designed by, and/or positively impact the communities most impacted by climate change also have strong appeal.

Interested parties are encouraged to attend informational webinars to find out more about the program to assess if it’s right for them. Get more information and register for the sessions here.

Session options and topics include:

• January 28, 2021, 11:00 AM – 12:00 PM EST – Overview of Venture For ClimateTech, its benefits, and how to apply with Managing Director, Jacqueline Ros Amable.
• February 9, 2021, 11:00 AM – 12:00 PM EST – How support and funding at the very early stage can accelerate businesses, with Venture For ClimateTech Sr. Manager, Chante Harris, and CEOs of climate tech companies who took advantage of similar programming.
• February 25, 2021, 7:00 PM EST – 8:00 PM EST – A Question and Answer session on the application process and program requirements with Managing Director, Jacqueline Ros Amable, and Devin Sandon, Operations.

The recruitment period closes on March 12, 2021 at 5:00 PM EST. Select applicants will be invited to participate in a Bootcamp For ClimateTech that will result in the final selection of 10 companies for Cohort 1. Participants in Cohort 1 will be announced on April 22, 2021.

Benefits of participating in the Venture For ClimateTech studio + accelerator include:

• Non-dilutive funding: Initial investment of $25k and up to $100k of an investment-matched grant
• Access to a network of mentors, EIR’s (Entrepreneurs in Residence), and strategic connections for paths to success
• Training and team building assistance with financial support for early hires
• Community growth and exposure through the larger climate tech ecosystem under the For ClimateTech umbrella
• Educational sessions related to investor readiness
• Brand and narrative building, and increased exposure to key stakeholders
• Introductions to additional programming

Apply to Venture For ClimateTech here.

For more information on For ClimateTech, including Venture For ClimateTech and Scale For ClimateTech, and to sign up to receive program updates and news, visit ForClimateTech.org.

About For ClimateTech

The For ClimateTech initiative, which includes Venture For ClimateTech and Scale For ClimateTech, is supported by the New York State Research and Development Authority (NYSERDA), and is administered by non-profit entrepreneurship catalyst NextCorps and impact innovation company SecondMuse. The goal of For ClimateTech initiatives is to accelerate innovations likely to have substantial climate impacts for all, and limit greenhouse gas emissions to 40% of 1990 levels by 2030 as established by The Climate Leadership and Community Protection Act of New York State.

Venture For ClimateTech Leadership

Jacqueline Ros Amable
, Managing Director – Amable is a former founder in the hardware space via Revolar. She is one of the first Latinas to raise millions from investors such as Foundry Group and Techstars. She previously covered the Americas region for Techstars, helping grow innovation ecosystems from Canada through Argentina.

Chante Harris
, Sr. Manager – Harris is a go-to-market strategist who has helped numerous global climate related companies launch and grow in New York State. She is also the founder of the Women of Color Collective in Sustainability.

Devin Sandon
, Operations – Sandon has spent the last five years scouting, coaching, and supporting early-stage climate innovators. He was part of the original NextCorps administered proof-of-concept program, Nexus-NY, that served founders at this business stage.

Media Contacts:

For more information, media, or digital content please reach out to our Marketing and Community Relations Specialist, Chris Carpenter, or media relations support, Shannon Wojcik.

Chris Carpenter
585-214-2424
[email protected]

Shannon Wojcik
585.831.6267
[email protected] 

TORONTO, Jan. 14, 2021 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra”) (TSX: CG) will host a conference call and webcast of its 2020 fourth quarter and year-end financial and operating results at 9:00 AM Eastern Time on Wednesday February 24, 2021. The results are scheduled to be released before the market opens on Wednesday, February 24, 2021.

• North American participants may access the call toll-free at +1 (888)-754-4430.
• International participants may access the call at +1 (416)-641-6701.

The conference call is being webcast by Intrado and can be accessed live at Centerra Gold’s website at www.centerragold.com. Presentation slides of the fourth quarter results will also be accessible on Centerra Gold’s website at www.centerragold.com

An audio recording of the call will be available approximately two hours after the call via telephone until midnight Eastern Time on Wednesday, March 3, 2021. The recording can be accessed by calling (416) 626-4100 or (800) 558-5253 and using the passcode 21989633. In addition the webcast will be archived on Centerra Gold’s website www.centerragold.com.

About Centerra Gold

Centerra Gold Inc. is a Canadian-based gold mining company focused on operating, developing, exploring and acquiring gold properties in North America, Asia and other markets worldwide and is one of the largest Western-based gold producers in Central Asia. Centerra operates three mines, the Kumtor Mine in the Kyrgyz Republic, the Mount Milligan Mine in British Columbia, Canada and the Öksüt Mine in Turkey. Centerra’s shares trade on the Toronto Stock Exchange (TSX) under the symbol CG. The Company is based in Toronto, Ontario, Canada.

Additional information on Centerra is available on the Company’s web site at

www.centerragold.com
and at SEDAR at www.sedar.com.

A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/0e6c1532-f35b-400e-98c8-2e184c8759d1

For more information:
John W. Pearson
Vice President, Investor Relations
(416) 204-1953
[email protected]

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an agreement with Lentigen Technology, Inc. (“Lentigen”), a wholly-owned subsidiary of Miltenyi Biotec B.V. & Co. KG, to manufacture lentiviral vectors for Oncternal’s investigational ROR1-targeting CAR-T cell therapy program.

Lentigen is a leader in translating gene therapy products into the clinic, including design, construction and production of lentiviral vectors, from research through GMP manufacturing.

As part of the agreement, Lentigen will reserve capacity in 2021 to manufacture, test and release GMP lentivirus to support and accelerate the development of Oncternal’s CAR-T cell therapy program. 

“Lentiviral vectors are an essential component in the CAR-T cell manufacturing process. Lentigen has successfully developed a large-scale, chemically-defined, serum-free lentiviral vector manufacturing process that ensures high quality and conformity with regulatory requirements,” said Boro Dropulic, Ph.D., M.B.A., General Manager and Chief Science Officer of Lentigen Technology, Inc. “We are excited to support Oncternal by manufacturing lentiviral vectors for its ROR1-targeting CAR-T program and help bring these novel cell therapies to patients with cancer.”

“Oncternal is working on rapidly advancing its ROR1-targeting CAR-T cell immunotherapy program, and we are pleased to work with Lentigen that is widely recognized as a global leader in producing GMP lentiviral vectors for the biopharma industry,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “ROR1 has emerged as an important target for cancer therapy, and we believe that our ROR1-targeting CAR-T program holds significant promise for patients with both hematologic cancers and solid tumors. Our goal is to achieve first-in-human dosing of the ROR1-targeting CAR-T therapy in the second half of 2021.”

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.

Forward-Looking Information

Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Oncternal’s current beliefs and expectations. Forward looking statements include statements regarding Oncternal’s beliefs, goals, intentions and expectations including, without limitation, the timing and ability of Lentigen to manufacture lentiviral vectors; Oncternal’s belief that ROR1-targeting CAR-T therapies hold significant promise for patients with hematologic cancers and solid tumors; the timing of any human dosing of its ROR1-targeting CAR-T therapy; and other statements regarding Oncternal’s development plans. Forward looking statements are subject to risks and uncertainties inherent in Oncternal’s business, which include, but are not limited to: the parties must negotiate and execute a master services agreement and related agreements prior to Lentigen initiating manufacturing of the lentiviral vectors; Oncternal’s dependence on Lentigen to manufacture the lentiviral vectors; the COVID-19 pandemic may disrupt Oncternal’s or Lentigen’s business operations; uncertainties associated with the preclinical and clinical development of the CAR-T cell therapy program; and other risks described in Oncternal’s prior press releases as well as in public periodic filings with the U.S. Securities & Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Oncternal Contacts:

Company Contact

Richard Vincent
858-434-1113
[email protected]

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
[email protected]

Source: Oncternal Therapeutics, Inc.

​LOS ANGELES, Jan. 14, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Magnite, Inc. (“Magnite” or the “Company”) (NASDAQ: MGNI) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The investigation focuses on whether Magnite issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Magnite is the subject of a research report released by Spruce Point Management on January 7, 2021. It is alleged in this Spruce Point Management report that before its merger with Rubicon, which formed Magnite, Telaria suffered from business woes. It is also alleged that prior to the merger Rubicon also suffered from deep business problems. Discrepancies are also alleged in this report in regard to Telaria’s 2019 Capital Expenditures and the removal of $9.3 million in “Other Assets” by Magnite after the merger. The report alleges that Magnite utilized questionable financial reporting methods in order to hide Telaria’s financial problems. Shares of Magnite dropped by more than 6% on the same day, based on this news.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising